MATX heads into its May 1 earnings release with a fresh bullish call from Wall Street and shorts in retreat — a setup that gives the stock an unusually clean runway into the print.
The most notable development this week is the timing of JP Morgan's coverage initiation. On April 27, the bank launched with an Overweight rating and a $230 price target — just days before Q1 results are due. At $175.51, that target implies roughly 31% upside, and it lands above even the current Street mean of $220. Stephens, which raised its target to $213 back in January, remains constructive. The overall analyst consensus is a buy, and the analyst recommendation differential ranks in the 93rd percentile relative to the broader market — meaning the Street is more uniformly positive on MATX than it is on almost any other name it covers. The valuation story is modest rather than stretched: the trailing P/E has climbed to 12.6 over the past month, up about one multiple point in 30 days, but EV/EBITDA has actually compressed slightly to 8.1. The bears point to a previously flagged Ocean Transportation income drop and a 14.6% year-over-year decline in China volumes. Bulls counter with the strong revenue momentum in recent quarters. The bull/bear data predates this year's tariff turbulence, so both cases carry the caveat of an evolving trade backdrop.
Shorts have been pulling back. Short interest now covers about 3.1% of the free float — low enough that it's not a primary story, but the direction is telling. From a mid-April peak above 1.08 million shares short, the position has unwound to roughly 956,000 shares, a drop of more than 10% in around two weeks. That covers the post-tariff-shock surge entirely. The borrow market is not signalling any squeeze pressure: cost to borrow is a negligible 0.47%, and lending availability remains very loose, with the lending pool well below its 52-week high utilization of 7.8%. The ORTEX short score, at 36.3, is below the midpoint of its range — consistent with shorts retreating, not pressing.
Options positioning tells a different story, and it's worth naming the contrast. Despite the bullish analyst catalyst, the put/call ratio has actually moved lower over the past month — from readings above 11 in late March to 5.56 now. That sounds alarming in isolation, but it represents a step toward normality: the 20-day average PCR is 6.5, and the current reading is more than one standard deviation below that. Options traders are less defensively positioned than they were even two weeks ago, which is consistent with the de-risking seen in short interest. The 52-week PCR range runs from 0.07 to 17.5, so the current level is firmly in the middle.
The stock has had a strong month. MATX is up 11% over the past four weeks, recouping all of the April tariff-shock selloff and then some. The week-on-week gain of 2.8% was roughly in line with peers: GNK gained 6% on the week, PANL rose 5.5%, and DSX added 1.6%. The recent earnings history adds texture: the last print in February produced a 3.4% one-day gain, and the November 2025 release drove a 9.9% jump the next session. Three of the four most recent prints were positive on the day. The factor score for EPS surprise ranks in the 82nd percentile — Matson has a track record of beating estimates.
The institutional holder base is stable and conventional: BlackRock at 16.7% and Vanguard at 12.1% dominate the register, with American Century adding 147,000 shares in the most recent quarter. Insider activity from March showed broad-based selling across senior vice presidents and the Chief Commercial Officer, with net proceeds above $11 million over 90 days. That cluster of March insider selling, at prices in the $148–$167 range, looks like ordinary post-vest activity at levels well below where the stock trades today.
The Q1 print on Thursday will likely pivot on how management characterises current China volume trends and whether Matson's premium Hawaii and Alaska lanes are holding rate discipline in a tariff-disrupted environment — two factors the JP Morgan initiation will quickly be judged against.
See the live data behind this article on ORTEX.
Open MATX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
